Key result
Inherited platelet disorders, such as Glanzmann thrombasthenia and Bernard-Soulier syndrome, provide critical insights into the molecular basis of primary hemostasis and antithrombotic drug development.
Answers are grounded in this paper and cite their sources.
Understanding the molecular basis of inherited platelet disorders like Glanzmann thrombasthenia and Bernard-Soulier syndrome has aided in the development of new antithrombotic therapies.
Introduction Genetic defects of platelets give rise to bleeding syndromes of varying severity. Affected areas of platelet function include the glycoprotein (GP) effectors of adhesion and aggregation, primary receptors for agonists, signaling pathways where messages are transmitted to targets elsewhere in the membrane or within the platelet, dense- and α-granule secretion, ATP production, and the expression of procoagulant activity. Glanzmann thrombasthenia (GT) and Bernard-Soulier syndrome (BSS) are the best-characterized platelet diseases and will have a major place in this review. GT is caused by abnormalities of platelet membrane GP IIb-IIIa (integrin αIIbβ3), resulting in absent platelet aggregation. BSS is caused by abnormalities of the GP Ib-IX-V complex, resulting in a loss of platelet adherence to vessel wall subendothelium. The disorders affecting platelet morphology, which give rise to the so-called giant platelet syndromes, are also considered. Studies on platelet disorders are significant because the knowledge gained has provided a better understanding of the molecular basis of primary hemostasis and has helped in the development of new drugs for use in antithrombotic therapy. In 1987, this author gave the inaugural State-of-the-Art lecture at an International Society of Thrombosis and Haemostasis meeting.1 At that time, the application of molecular biology procedures to the study of platelet disorders was just beginning. Now, 12 years later, some of these data will be reviewed and the recent advances discussed.
No takes yet. Share an insight, caveat, or question.
Alan T. Nurden (1999) conducted a review in Inherited platelet disorders. Inherited platelet disorders, such as Glanzmann thrombasthenia and Bernard-Soulier syndrome, provide critical insights into the molecular basis of primary hemostasis and antithrombotic drug development.
Synapse has enriched 10 related papers. Consider them for comparative context: